CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will present at the Jefferies 2017 Global Healthcare
Conference on Friday, June 9, 2017, at 11:30 a.m. ET. The conference
will be held at the Grand Hyatt New York in New York City.
A live webcast of the presentation can be accessed on the Investors &
Media section on the Dicerna website at www.dicerna.com.
An archived replay of the webcast will be available on the Company's
website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the discovery and development of innovative ribonucleic acid
interference (RNAi)-based therapeutics for diseases involving the liver,
including rare diseases, chronic liver diseases, cardiovascular
diseases, and viral infectious diseases. The Company is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad pipeline in
these core therapeutic areas, focusing on target genes where connections
between target gene and diseases are well understood and documented. The
Company intends to discover, develop and commercialize novel
therapeutics either on its own or in collaboration with pharmaceutical
partners. For more information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005235/en/
Rx Communications Group
Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media